4//SEC Filing
Babu Yarlagadda S 4
Accession 0001127602-20-006501
CIK 0000882796other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 5:03 PM ET
Size
5.5 KB
Accession
0001127602-20-006501
Insider Transaction Report
Form 4
Babu Yarlagadda S
VP Drug Discovery
Transactions
- Award
Emp. Stock Option (Right to Buy)
2020-02-14+31,500→ 31,500 totalExercise: $11.13From: 2020-02-14Exp: 2024-12-22→ Common Stock (31,500 underlying)
Footnotes (1)
- [F1]On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001452635
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 5:03 PM ET
- Size
- 5.5 KB